text:
Home Android
How to know which apps use more RAM on an Android mobile
In Windows, if you want to see how much memory a program is using, checking it is as easy as opening the Task Manager. On Android, the system does not work exactly the same, but you can also view memory usage of applications, although it is a little more hidden.
If your mobile does not have much RAM and you want to identify those applications that consume the most memory, you can check the data from the options for Android developers.
1. Activate developer options
In the past, some layers and ROMs of Android showed you the memory usage directly in the recent view, although today it is more rare to find the data. However, there is still a foolproof way to see memory usage and it should be available on almost all Android phones: from developer options.
Therefore, before you can use the memory of the different applications, you must activate the Android developer options, if you have not activated them before. The way to do it has been the same for years: go to the section System settings, enter Phone information and tap seven times, quickly, on Build number.
Once this is done, you will see a notice indicating that developer options have been activated. You will find them as a new menu that was not previously in the section System settings, although some layers include it as a separate menu. If you can't find them, use the settings finder at the top.
2. Check memory usage
With the developer options active, the next step is to enter these options, which are generally found in the section System. Then touch on Memory, which in most cases is the first option shown, at the top.
Once this is done, you will see the general status of the mobile's RAM, including current and average use. If you want to see the use for each application, you need to enter Memory used by applications.
Now yes, you will see the average RAM memory usage of each application, including system ones. Android gives you the option to view memory usage data in different time ranges: 3 hours, 6 hours, 12 hours or 1 day.
By default, Android sorts the list of applications by average use, although with the menu ⋮ at the top you can change so that sorted by maximum memory usage and not the average. In this way, you will be able to identify the apps that occupy most of your mobile's RAM in specific cases (such as when you are using them intensively).
'Dead Empire: Zombie War', a mobile strategy game with multiplayer combat...
'Hyperball Legends': una alternativa a 'Rocket League' gratuita para Android
'The Mandalorian' comes to Google's augmented reality in the form of...
'Todo' is a free task manager where design and simplicity prevail
'Your phone' already allows the Samsung Galaxy to run several Android...
10 apps and websites to find out whose phone number is
How to prevent the mobile screen from automatically turning off on Android
how to delete by all Google apps and services from an Android mobile
How to customize the app icons in the settings menu on a Samsung mobile
How to add, edit or delete different users on an Android mobile phone or tablet
How to disable sending statistics to Google from an Android
How to find a lost or stolen Android mobile
If notifications do not go well for your Huawei mobile, the fault could be with PowerGenie: so you can disable it


Nathan Blecharczyk cofounded peer-to-peer room and home rental company Airbnb with Joe Gebbia and Brian Chesky in 2008.
Blecharczyk, who is chief strategy officer, was the company's first engineer.
Airbnb now operates in over 81,000 cities in 191 countries. With 5 million listings worldwide, it has rented to 300 million guests and counting.
Gebbia brought on Blecharczyk, who was a former roommate in San Francisco, as cofounder and chief technology officer.
Blecharczyk, who lives in San Francisco with his family, is an Airbnb host.
It's better to have 100 users that love you than 1,000 users that like you. Find your evangelists and build for them.
Related by financial asset: Airbnb, Inc.


To that point, the EFF showed that the stories on the R-J web site whose rights have been assigned to Righthaven still retain the Review-Journal's copyright notice.
Shady Lady owner Davis said the law even prohibited advertising in the R-J for housekeepers and bartenders.
One of the biggest hurdles the Mercury faces is overcoming the perception that it is merely an arm of the R-J.
But Geoff Schumacher, the Mercury's editor and publisher, says the paper won't shy away from casting a critical eye on the R-J if necessary.


A credit report is an important document and it gives all the details of your credit and other financial activities. Lending companies, banks, employers, and other companies judge you on the basis of your credit report. Your credit report has vital information which reflects on your financial status and creditworthiness. Whenever you apply for a loan or a mortgage your credit report is the first thing that is scrutinized. As this report is so crucial it is important that you check it and make sure it is free of any errors. If you find any error you are empowered by FCRA (Fair Credit Reporting Act) to file a credit report dispute, in order to correct the errors.
There are three separate bureaus who are responsible for collecting data and preparing your credit report. As per law you are entitled to get one copy of your credit report annually for free, from each of these bureaus. Once you have checked these reports, and have found certain mistakes you have to immediately send the credit report dispute, to the concerned bureau and the provider who has supplied the bureau with that information. The credit report dispute should be in writing and should be accompanied by all the documents which will prove the mistake.
In the credit report dispute you should clearly state your name and address and the information in the report which you found was erroneous. It will be much clearer if you attach a copy of your credit report, highlighting the information which you are disputing. Make copies of any cancelled checks or other statements which will support your claim and attach them with the credit report dispute. Always send only the copies and keep the originals for your own records.
After you have carefully prepared your credit report dispute with the appropriate attachments make one copy of the letter for your records and send the original only by certified mail, requesting a return receipt. This provides you with the proof of sending the dispute and of the bureau's receipt of the same.
After the receipt of your credit report dispute, the bureau has a time limit of thirty days to investigate the matter with the provider who has given the erroneous information. If your claim proves to be valid the bureau will send the corrected copy of the credit report to you. You can also instruct the bureau to send the corrected copies to all the companies that have accessed your wrong report.
Well, my bank sends my credit report every month not on freely basis. It�s good to have the monthly report that way you have the idea that what you are doing with your credits and how you can reduce your unnecessary expenses.


12/7/15 [6BOX PICK YOUR TEAM] #10 - 2015 Panini Immaculate NFL Football - PEYTON #/5 AUTO!
12/18/15 [6BOX (1/2 case) PICK YOUR TEAM] #7 - 2015 Topps Tribute SE MLB - POMPEY PLATE!
04/15/16 [6Box (1/2 case) PICK YOUR TEAM] #12 - 2016 Topps Museum Collection MLB Baseball - BOOK!
12/1/15 [6BOX PICK YOUR TEAM] - 2015 Panini Immaculate NFL - GURLEY PAST/PRESENT!
12/7/15 [9BOX (Inner) PICK YOUR TEAM] #4 - 2015 Topps Triple Threads NFL - LUCK + WILSON BOOK!


Be watchful and cautious of both others' actions and your own. Stand ready to protect yourself from those who may covet what you have or seek to harm those you care for, but also be vigilant and watchful of your own actions lest you be the one doing harm. Weigh your actions. Be sure you act wisely. Be sure you have done all that needs to be done before moving forward. Leave nothing to chance lest all you have nurtured and cherished be undone by your own lack of vigilance.
Are you holding on to beliefs and notions that no longer serve you? Are you blocking your own growth and forward momentum because you fear to end a chapter in your life? It is time to release all that you hold onto that no longer serves. It is time to say goodbye to all that no longer has a place or purpose in your life. It's time to have an emotional, or physical, spring clean. It's time to let go of the past so you can be open to what the future may bring.
Take the time to nurture the things you care about so that they may flourish and grow. Your hopes, your dreams, your body, your mind, your spirit, your creations, and your relationships; all that is you needs to be cherished, loved, honored and respected. Without care and attention, these aspects of self can fall into a state of neglect that does only harm to both you and the world around you. Nurture them, and they will bring you peace and fulfillment.


Newly added listing. Check this page if you visit this web site regularly.
RM18 psf The subject property is a freehold, converted industrial land along the Tanjong Malim - Kuala Lumpur trunk road. It is only 70 km from Kuala Lumpur city centre and one hour drive away.
The subject property is currently a durian farm.
The subject property is a freehold converted commercial land located along the Port Dickson seaside trunk road about 6 km towards the south. An elevated view from the subject property will have a view of the famous Avillion Resort Hotel and the beautiful straits of Melaka. This commercial land has a plot ratio of 4 and above. Part of the land is having a 160 feet road frontage onto the trunk road.
RM 30 psf The subject property is located very near to Seremban town and among low density area. Approval has been obtained to build low rise condo.
RM5.8 million This is a factory lot in the heart of Chan Sow Lin industrial park. This park is now under transformation into a commercial hub because of the proximity to 1Bandar Malaysia. It is a leasehold land with a remaining lease of 44 years. The price worked out to be around RM530 p.s.f.
This is a mixed development land along the Middle Ring Road 2, ( MRR2 ). Flat land. It has a plot ration of 6 and has a view of 2 lakes in the vicinity.
This is a development land along the MRR2 (Middle Ring Road 2). Flat land. Can be converted to mixed development.
RM14 psf The land is located north-east of Kapar town. This is one of the larger parcel of agriculture land available which is near to Kuala Selangor, Kapar, Meru and Ijok.
Freehold agriculture land zoned industrial. Cheap because the land shape is triangular.
This is a freehold agriculture land located in the Sungai Dua new village along the Karak Highway. The land is 80 km from Kuala Lumpur city centre and only one hour's drive from here. The land is on a hill beside this Chinese new village so getting workers here is relatively easy. There is also an orang asli village nearby. Very suitable for planting durian. Travelling from KL city centre to this place along the Karak Highway is relatively fast.
The subject property is an oil palm small holding planted with 3-year old palm tree. It is fronting the main Cheruh - Cameron road. The terrain is flat in the front portion (about 40%) and the balance 60% is on a slope but not hilly. There is an oil mill a few kilometres away.
The subject property is only few hundred metres from Raub-K.Lipis main road. Planted with old rubber trees. Asking RM60k/acre (nego).
RM 3.1 million The subject property is located just off the Sg Buloh - Ijok trunk road and about 1.7 km from the town. This is a converted freehold industrial land.
RM 30 million The subject property is a converted commercial land located along the LDP. If need be, the owner can sell another 1-2 acres adjoining agriculture land.
Sold ! An Oil Mill located in the state of Johor. It comprises 40 acres of oil palm land and machinery and a fibreboard plant. Detail will be supplied to genuine buyer.
The subject property is an oil palm estate located in Gurun. Detail will be supplied to genuine buyer.
RM 7.5 million The subject property is located across the road and opposite University Nottingham, Semenyih. It comprises 2 lots, 9 acres plus and 4 acres adjoining only at one corner of the land. There seems to be legal access to the 9 acres plus but we are not sure about the 4 acres.
RM36.3 million The subject property is located in Bukit Selambau, Gurun, Kedah. It is fronting Jeniang - Bukit Selambau trunk road. It is about 27 kilometres south-east of Gurun town. Price negotiable.
The subject property is located right in Seremban town centre just next to the General Hospital. The land was approved for condominium in 1997 but approval has since lapsed.


If you are planning to visit Thailand for more than 30 days you will need to obtain a visa in advance. The Thailand Tourist Visa entitles you to stay for up to 60 days in Thailand to holiday and travel, but it does not permit you to work in Thailand. If you're visiting Thailand for business purposes you will need a Business (Non-Immigrant) visa which allows you to stay for up to 90 days.
*Currency & price depend on client's passport country as follows: Ireland/ United-Kingdom/ Australia/ Canada.
What are the Thailand visa requirements?
If you plan to stay in Thailand for less than 30 days, you don't need a visa. For longer visits, or if you visit Thailand on business purposes - a visa is required. Contact Visa First and apply online! Check the allowed duration of your visa-free stay: go to eligibility tab.
How long does it take to get the Thai visa?
A maximum of 3 working days is required by the embassy to process your application after all the relevant documents are received. Allow two more days for postage.
Depending on how many entries your visa allows - you can spend up to 60 days on each. Days left from your previous entry do not count.
Visa First is a private migration agency with over 10 years of experience in visa processing. We employ a big team of experts all focusing on getting your visa granted. We act as a 3rd party between you and the immigration authorities - you get professional representation and access to the knowledge of our visa advisers and licensed migration agents.
If applying from another country - please contact us on 866 772 9245 (local phone based on your device network location) or request a callback.
View the FAQs tab to find answers to more questions!
Cheers for all your help. I'd just like to say I have found visafirst very good people to do business with. Very helpful, fast and efficient. Thanks for returning my call at the time you said you would and for advising me on the pack for New Zealand which includes the bank account and IRD number. You have made my heading to New Zealand less stressfull. Much appreciated.
Hi Liz, I wanted to thank you for all your work and dedication to our case over the last year.I know that it's your job however I just wanted to tell you that you are good at your job and keep it up. Its so nice to deal with someone so empathic and helpful as you were. Things going smoothly at the mo so thank you.


Going Home – . . Just Thinking . .
It had different feel this morning, riding in on the shuttle to Mayo World. I wasn't contemplating being fried, poked or prodded. I was thinking of my Northern Cal. friend; friend might be too strong of word, but acquaintance isn't right either. I think we made a connection, it was a short hook up, kind of a password type of thing. A classic example of 'you had to be there'. It was almost like meeting someone at the end of pilgrimage to a healing shrine. This was not home, home was somewhere else entirely, and would never fit exactly the same way again. How close the fit would be was a forbidden topic we carefully danced around. He knew Kansas City was mostly in Missouri, a fact he assured me was rare on the west coast. I asked him if he came way out here because Mayo was one of the best. He said no, if he wanted one of the best he he would have went to Frisco or Arizona. He came here because it was the best. He ask if I knew whether the Cubs won. He explained his interest by saying all of Northern Cal. were Giants fans, enough said. He said you guys on the Missouri side guys don't think much of Kansas, it goes all the way back to the civil war. I responded, It's probably similar to your feelings toward the Dodgers." So you hate them. He retorted." Well, we changed conferences so the rivalry has loss some of it's animosity.
This was our third shared ride and our last. He had surgery yesterday and had one last dr. visit, then he was flying home. He was in obvious discomfort and said don't make the mistake I made. I was feeling pretty good, before the surgery, so booked my flight for the next day, got to get back to the farm you know. Big mistake, he cursed. How did the surgery go? I inquired. It was more extensive than they thought, but they're the best. I helped this proud man off the shuttle with his bag. He looked back and said, give yourself some time to heal, nodded and was gone. So this morning I wasn't thinking of all my activities awaiting at the shrine. I was thinking of my password buddy returning from his pilgrimage to his farm and wondered, what he was thinking.
Next postCan You Change the Past?


text:
Q: MongoDB db.serverStatus() has no storageEngine output I have an instance of MongoDB 4.0.6 with WiredTiger and the documentation says that db.serverStatus() has a storageEngine section in the output with some info on the Wired Tiger flags. On my instance there's no storageEngine section in the output at all. Am I missing something?
To be specific, I have a sharded cluster with a 3 node replica set where one of the nodes is an arbiter, which leads to an ever growing WiredTigerLAS.wt file when creating many records quickly. The documentation says we can turn off readConcernMajority with '--enableMajorityReadConcern false', which we have done. Does not stop the lookaside file growth. I'd like to check the status of that flag, and again following the documentation I'm using db.serverStatus(), but in contrast to the documentation the output contains no storageEngine section at all.
Maybe I should just change the arbiter into a data bearing node, but I was hoping to avoid the cost. Any help on this issue is appreciated.
Adding rs.status() (note that the secondary is currently resynching from the primary):
{
        "set" : "shardRS1",
        "date" : ISODate("2019-06-06T17:09:06.986Z"),
        "myState" : 2,
        "term" : NumberLong(66),
        "syncingTo" : "1b:27018",
        "syncSourceHost" : "1b:27018",
        "syncSourceId" : 0,
        "heartbeatIntervalMillis" : NumberLong(2000),
        "optimes" : {
                "lastCommittedOpTime" : {
                        "ts" : Timestamp(1559840946, 1),
                        "t" : NumberLong(66)
                },
                "readConcernMajorityOpTime" : {
                        "ts" : Timestamp(1559840946, 1),
                        "t" : NumberLong(66)
                },
                "appliedOpTime" : {
                        "ts" : Timestamp(1559840946, 1),
                        "t" : NumberLong(66)
                },
                "durableOpTime" : {
                        "ts" : Timestamp(1559840946, 1),
                        "t" : NumberLong(66)
                }
        },
        "members" : [
                {
                        "_id" : 0,
                        "name" : "1b:27018",
                        "health" : 1,
                        "state" : 1,
                        "stateStr" : "PRIMARY",
                        "uptime" : 177202,
                        "optime" : {
                                "ts" : Timestamp(1559840936, 1),
                                "t" : NumberLong(66)
                        },
                        "optimeDurable" : {
                                "ts" : Timestamp(1559840936, 1),
                                "t" : NumberLong(66)
                        },
                        "optimeDate" : ISODate("2019-06-06T17:08:56Z"),
                        "optimeDurableDate" : ISODate("2019-06-06T17:08:56Z"),
                        "lastHeartbeat" : ISODate("2019-06-06T17:09:05.722Z"),
                        "lastHeartbeatRecv" : ISODate("2019-06-06T17:09:05.263Z"),
                        "pingMs" : NumberLong(0),
                        "lastHeartbeatMessage" : "",
                        "syncingTo" : "",
                        "syncSourceHost" : "",
                        "syncSourceId" : -1,
                        "infoMessage" : "",
                        "electionTime" : Timestamp(1559662230, 1),
                        "electionDate" : ISODate("2019-06-04T15:30:30Z"),
                        "configVersion" : 2
                },
                {
                        "_id" : 1,
                        "name" : "1d:27018",
                        "health" : 1,
                        "state" : 2,
                        "stateStr" : "SECONDARY",
                        "uptime" : 177203,
                        "optime" : {
                                "ts" : Timestamp(1559840946, 1),
                                "t" : NumberLong(66)
                        },
                        "optimeDate" : ISODate("2019-06-06T17:09:06Z"),
                        "syncingTo" : "1b:27018",
                        "syncSourceHost" : "1b:27018",
                        "syncSourceId" : 0,
                        "infoMessage" : "",
                        "configVersion" : 2,
                        "self" : true,
                        "lastHeartbeatMessage" : ""
                },
                {
                        "_id" : 2,
                        "name" : "1c:27018",
                        "health" : 1,
                        "state" : 7,
                        "stateStr" : "ARBITER",
                        "uptime" : 177202,
                        "lastHeartbeat" : ISODate("2019-06-06T17:09:05.933Z"),
                        "lastHeartbeatRecv" : ISODate("2019-06-06T17:09:05.468Z"),
                        "pingMs" : NumberLong(1),
                        "lastHeartbeatMessage" : "",
                        "syncingTo" : "",
                        "syncSourceHost" : "",
                        "syncSourceId" : -1,
                        "infoMessage" : "",
                        "configVersion" : 2
                }
        ],
        "ok" : 1,
        "operationTime" : Timestamp(1559840946, 1),
        "$gleStats" : {
                "lastOpTime" : Timestamp(0, 0),
                "electionId" : ObjectId("000000000000000000000000")
        },
        "lastCommittedOpTime" : Timestamp(1559840946, 1),
        "$configServerState" : {
                "opTime" : {
                        "ts" : Timestamp(1559840926, 1),
                        "t" : NumberLong(35)
                }
        },
        "$clusterTime" : {
                "clusterTime" : Timestamp(1559840946, 1),
                "signature" : {
                        "hash" : BinData(0,"AAAAAAAAAAAAAAAAAAAAAAAAAAA="),
                        "keyId" : NumberLong(0)
                }
        }
}

Adding rs.conf():
{
        "_id" : "shardRS1",
        "version" : 2,
        "protocolVersion" : NumberLong(1),
        "writeConcernMajorityJournalDefault" : true,
        "members" : [
                {
                        "_id" : 0,
                        "host" : "1b:27018",
                        "arbiterOnly" : false,
                        "buildIndexes" : true,
                        "hidden" : false,
                        "priority" : 1,
                        "tags" : {

                        },
                        "slaveDelay" : NumberLong(0),
                        "votes" : 1
                },
                {
                        "_id" : 1,
                        "host" : "1d:27018",
                        "arbiterOnly" : false,
                        "buildIndexes" : true,
                        "hidden" : false,
                        "priority" : 1,
                        "tags" : {

                        },
                        "slaveDelay" : NumberLong(0),
                        "votes" : 1
                },
                {
                        "_id" : 2,
                        "host" : "1c:27018",
                        "arbiterOnly" : true,
                        "buildIndexes" : true,
                        "hidden" : false,
                        "priority" : 0,
                        "tags" : {

                        },
                        "slaveDelay" : NumberLong(0),
                        "votes" : 1
                }
        ],
        "settings" : {
                "chainingAllowed" : true,
                "heartbeatIntervalMillis" : 2000,
                "heartbeatTimeoutSecs" : 10,
                "electionTimeoutMillis" : 10000,
                "catchUpTimeoutMillis" : -1,
                "catchUpTakeoverDelayMillis" : 30000,
                "getLastErrorModes" : {

                },
                "getLastErrorDefaults" : {
                        "w" : 1,
                        "wtimeout" : 0
                },
                "replicaSetId" : ObjectId("5c8743e6b6916b268c071e3a")
        }
}

redpajama_set_name: RedPajamaStackExchange


Ontario finance minister Vic Fedeli announced $15 million will be split to the province's municipalities to help cover cannabis costs in January.
TORONTO – The Ontario government will start distributing millions in funding in January to help municipalities cover costs associated with legalizing recreational cannabis.
In a letter to the Association of Municipalities of Ontario, Finance Minister Vic Fedeli says $15 million will first be spilt among the province's municipalities at the start of the new year, with funding allocated on a per household basis and all communities receiving at least $5,000.
An additional $15 million will then go to municipalities that agree to host cannabis retail stores within their boundaries.
The Progressive Conservative government has given communities until Jan. 22 to decide whether they want to opt out of hosting the stores, which are expected to start operating in April.
Fedeli says the province will set aside an additional $10 million as a contingency fund to deal with any "unforeseen circumstances" related to marijuana legalization that municipalities might encounter.
He says the funds for municipalities can only be used for a prescribed set of circumstances including heightened enforcement, increased response to public inquiries, increased paramedic or fire services and by-law or policy development.
Fedeli also said that if Ontario's portion of the federal excise tax on recreational marijuana exceeds $100 million, the province will give half of the surplus to municipalities that have not opted out of hosting stores.
The federal government legalized recreational cannabis on Oct. 17. In Ontario, a government-run online store is currently the only way to purchase recreational pot.


text:
Q: Entity Framework Core 6 - setting the decimal precision using DBContextOptionsBuilder I want to set decimal precision and scale for all decimal properties in my model.
I know one of the way to do this in EF Core 6 is to override ConfigureConventions,
protected override void ConfigureConventions(
    ModelConfigurationBuilder configurationBuilder)
{
    configurationBuilder.Properties<decimal>()
        .HavePrecision(18, 6);
}

However, I do not have access to underlying DBContext to override or subclass it. I am using it as part of nuget package.
I have access to pass only DbContextOptionsBuilder in my application's Startup class to some method from underlying framework method which accepts parameter of type DbContextOptionsBuilder.
The underlying framework adds DbContext using AddDbContextPool method and passes DbContextOptionsBuilder received as a parameter. It is added to IServiceCollection.
public static void ConfigureMyAppServices(IServiceCollection services, Action<DbContextOptionsBuilder> configuration)
{
services.AddDbContextPool<MyAppDbContext>(configuration);
}

Here MyAppDbContext inherits from DbContext.
Is there a way to plugin conventions for the entire model using DbContextOptionsBuilder object.


text:
Steelers Flashback: Hines Ward Should've Been In The World Cup
By Alex Kozora
New series I'll pop up from time to time to try and make the offseason at least feel a little quicker.
The Internet is a great place for some wayback Pittsburgh Steelers' games that you and I have long forgotten about (or not been alive to remember in the first place). That in mind, we'll occasionally post clips of random – and sometimes meaningful – plays from at least a decade ago.
France knocked off Croatia in the World Cup Final today, 4-2. I know he wouldn't have been eligible but I think the Croatians could've used Hines Ward hope. For one play in 2005, he was less football player, more Pelé.
Too bad for the Steelers those futbol skills worked against them. It's 2005 and Tommy Maddox is trying to lead a late drive to beat the Baltimore Ravens. Maddox, admittedly, probably forces this throw back shoulder to Ward, blanketd by corner Chris McAlister, who manages to break it up.
Instead of the ball falling incomplete, like literally any other time this would've happened, it clanks off Ward's left foot and careems back into the air.
Terrell Suggs, an apparent ageless wonder, makes a heck of a play to dive for the ball and pick it off, killing the drive.
Ok, I'll shut up and let you guys look at it because that's what really matters here.
"It was a fluke, man," Ward told the PPG after the game. "I tried to bat it down with my left [hand] and it kicked off my foot. Fluke play."
Baltimore wouldn't score on the drive but won it in overtime off a Matt Stover 44 yard boot.
That loss began a three-game skid for Pittsburgh, getting dangerously close out of the playoff picture. But they righted the ship, winning the final four, and as Ben Roethlisberger promised Jerome Bettis, ended in a Super Bowl victory.
All's well that ends well. A play we can laugh about now but at the time, one that cast serious doubt on the Steelers' chances.
Related Items:Hines Ward, Pittsburgh Steelers, Terrell Suggs, Tommy Maddox

redpajama_set_name: RedPajamaCommonCrawl


For a long time, we were totally internally focussed and now bring to market the vast expertise gained over the years.
We believe in keeping things simple, efficient and uncluttered.
We understand that our success is tied to success of our clients. We combine business domain knowledge with technology expertise and proven methodologies to deliver high quality, cost effective results to maximize clients competitive benefits and yields. Our business solutions energize(enlighten) and encourage(empower) customer engagement(partnership) with real time information and collaboration.
To equip or supply with an ability; enable: Computers ... empower students to become intellectual explorers (Edward B. Fiske).
To give spiritual or intellectual insight to: Enlighten the people generally, and tyranny and oppression of body and mind will vanish like evil spirits at the dawn of day (Thomas Jefferson).
To give information to; inform or instruct..
One that is united or associated with another or others in an activity or a sphere of common interest. v.tr.
To bring together as partners; To be the partner of.
We increase the speed of doing business thus enabling people to be more productive and businesses to transform. Our aim is to become a trusted partner contributing to our customers success. Our delivery solutions meet all quality requirements of client.
Simple to use, yet powerful enough to offer flexibility in today's competitive market. We believe in improving the bottom line results. Risersoft has the knowledge and insights to uncover the opportunities and commitment to see them through. Company has never lost its vision of helping manufacturing run more smoothly, productively and profitability. Our specialization, dedication and devotion to building our business and yours with high quality people, products and services are testament to our ongoing goal of strengthening our reputation.


text:
News Sports GameTimePA FlipSidePA Opinion Obituaries E-Edition Legals
Regents' Glen members, residents hopeful in new era
A Sunday meet and greet showed enthusiasm for new ownership of the Spring garden Township gated community.
Flint L. McColgan
fmccolgan@ydr.com
The wine flowed and the hors d'oeuvre were gobbled up Sunday by a roomful of Regents' Glen residents and country club members ecstatic about a new era for the gated community in Spring Garden Township.
"We've been waiting and praying for this," said Carolyn Conley, who has lived in the community with her husband, Doug, for 14 years.
Regents' Glen hasn't issued paychecks since June, employees say
Just behind her, the large windows of the community's visitors and information center show a vista of a winding road in front of a lake where water fowl swim around the central fountain. Just at the other side of the lake was the first phase of the community.
Doug Conley said it was a dusty beginning as Regents' Glen expanded into what it is today. But the sense of community, "the atmosphere, the camaraderie," was strong.
To Andrew Lockhart, who moved to the community in January 2005 with his wife, the community was "a really neat thing," where all the neighbors got to know each other at the country club grille and a resident could drive their golf cart anywhere they want.
That's how the place's founders envisioned the place, said Ann McCormack Reynolds, who is the daughter of founder Web McCormack.
Wedding plagued by venue concerns, a success at Regents' Glen
"There is a treasure nestled in the soft, rolling hills of southern Pennsylvania. A treasure that has more value than gold because it truly is one-of-a-kind. The treasure: A lifestyle for active adults that is rich in life's comforts and and pleasures. The place: Regents' Glen," so says a brochure from the late 1990s.
The name was chosen by an advertising firm whose presentation impressed first owners McCormack, brother Jim McCormack and Dr. Ray Wilson. The "regents" portion was chosen from the idea of a "board of regents" because it suggests prestige, Reynolds said, where the "glen" was chosen because of the glen found on the back nine.
Ground broke in June 1996, Reynolds said. Through subsequent owners the original plan for "a way of life" reminiscent of the gated communities those with means would winter in in Florida became less of a focus, Reynolds said.
Regents' Glen could avoid auction of property after Fla. judge's ruling
"This really was my dad, this was him and his vision," she said of McCormack, who died in 2014. "I didn't want my dad's legacy and vision to be lost."
But a new owner gives her hope.
Rod Krebs finalized his purchase of all the property's assets on March 11. The Glen Rock native owns Springfield Contractors, Inc., which performed part of the construction of Regents' Glen.
5 things to know about new Regents' Glen owner
"I'm really excited and honored that he bought the property," Reynolds said. "He was a part of it."
Krebs said that his family will be heavily involved in the project and has taken the input of different community boards and groups seriously in determining what residents and golfing and dining members want out of the place.
The golf course will open April 1. The grille will be back in mid-April and a return of fine dining at the Box Hill Mansion is planned.
The new ownership was greeted with enthusiasm Sunday.
"Too much turmoil over the last two, three years," said Gene McKay, resident with wife Pat for nine years and members for 13 years. "When we first moved here it was good. Had a great manager ... bringing in a lot of new members but then things got nasty after a while."
Regents' Glen finances, unease from residents employees
"He sees the potential that is here and he is willing to do what it takes to bring it to the vision that he sees for it," Pat McKay said of Krebs.
"We're really pleased that he had the foresight to rescue it and I think it's going to work out very well," said Judy Heaps.
"I have pulled more weeds in this community than I have in my whole life," Carolyn Conley said, "and that's because I love it and want it to be beautiful."


text:
One Click Away
October 18, 2021 | in Featured, Uncategorized
By Ricky L. Taylor
Ricky L. Taylor is a poet, author, and motivational speaker from Chester, PA. "Uncle Ricky," as he is called by his students and mentees, dedicates his life wholeheartedly to helping more youth in his hometown overcome the obstacles he faced: helplessness, hopelessness, insecurity, and confusion, and replace them with hope, help, security, and direction. Through the work of the Making A Change Group and other non-profit organizations, this budding entrepreneur has become one of the new faces for change in Delaware County. Follow Uncle Ricky (@UncRicky) on Instagram for performance updates, book releases, speaking engagements and community events.
"One Click Away" By Ricky L. Taylor
View the rest of their Chester Digital Stories here.
What is your Chester story?
Submit Idea Here
Public Access to Chester Digital Stories
Chester Digital Stories are a community resource – an opportunity for all of us to share experiences and promote continued conversation around a wide range of topics and issues relevant to the city of Chester, Pennsylvania. We encourage everyone to listen to and view our digital stories and share them with family and friends.
Use of Chester Digital Stories by individuals, organizations and institutions is restricted to non-commercial use. Educators, writers, filmmakers, scholars, and other interested individuals, organizations and institutions seeking to copy and/or use excerpts from or the entirety of any Chester Digital Story must request permission from the Chester Digital Story Advisory Board. Please contact Taylor Tolton-Kain at ttolton@pahumanities.org for complete information.
© 2022 Chester Made
Website Design by The 215 Guys
We won't overwhelm your inbox, and will provide you with succinct, important information about the community. Sign-up today!


"He who passively accepts evil is as much involved in it as he who helps to perpetrate it. He who accepts evil without protesting against it is really cooperating with it." —Martin Luther King Jr. How many more people have to die senseless deaths in this country? The time for action is long overdue.


At Kate Spade, the Make It Mine platform now gives customers 45 customizable bag design options, as well as the option to add accessories and monogramming to jewelry, bags and accessories. In stores, Kate Spade uses Perch technology to recreate the online product customization experience, by activating sensors when customers pick up a bag that can be customized. Once they do, a digital screen pulls up all possible embellishments, as well as a tutorial video demonstrating how to make a bag personalized. According to Kate Spade CMO Mary Renner Beech, Make It Mine draws about 120,000 interactions monthly, but the brand didn't offer any other figures.


Description: Smaller than "Trofie", "Trofiette" are a typical long and thin Ligurian pasta. The name is said to come from the Genoese strufuggiâ ("to rub"), the movement of the hand forming the typical curl while working the dough on the table. They are ideal with pesto, to which a trickle of extra virgin olive oil and Parmigiano Reggiano cheese can be added. Cooking time: 20 minutes.


text:
Vol. 8 No. 2 (2018): IJFPS /
On how Bohr model of hydrogen atom is connected to nuclear physics
Wladimir Guglinski Escola de Engenharia da Universidade Federal de Minas Gerais, Av. Presidente Antonio Carlos, 6627, Pampulha, Belo Horizonte-MG, Brazil
https://doi.org/10.14331/ijfps.2018.330113
Electric field structure, Modified Coulomb's law, Modified Bohr's hydrogen model
The atom model of Quantum Mechanics (QM) was conceived from an unsolved paradox. Indeed, Schrödinger's equation has been deducted by considering a free electron, but it is applied for the atom, where the electron is inside a potential. In order to eliminate the nonsense, quantum theorists proposed a ridiculous postulate: they claim it makes sense to use the equation because it gives results in agreement to experimental data. The unsolved paradox evidences that Schrödinger's equation cannot be applied to the physical conditions considered in the QM atom model, and that his equation actually requires some special conditions not considered in the theory (for instance, the electron helical trajectory, rejected by Heisenberg). The banishment of the aether has introduced several paradoxes in the development of Theoretical Physics. And because the theorists have neglected other paradox (from the mathematical probability the spectacular successes of Bohr's hydrogen atom cannot be accidental), these two unsolved paradoxes introduced dramatic consequences in the development of Nuclear Physics.
Guglinski, W. . (2018). On how Bohr model of hydrogen atom is connected to nuclear physics: Physics. International Journal of Fundamental Physical Sciences, 8(2), 44-53. https://doi.org/10.14331/ijfps.2018.330113
Vol. 8 No. 2 (2018): IJFPS
Copyright (c) 2020 International Journal of Fundamental Physical Science
Rahman Sharifi , Mahmoud Nikkhah Shamirzadi, Marl qualitative effects on the distribution of Quaternary deposits , International Journal of Fundamental Physical Sciences: Vol. 8 No. 4 (2018): IJFPS
Wladimir Guglinski, Re-evaluation of Fermi's theory of beta-decay , International Journal of Fundamental Physical Sciences: Vol. 8 No. 2 (2018): IJFPS
DOI: 10.14331/ijfps
MENDELEY / ELSEVIER
Most Read Articles (Days count)
The Ultimate Sophistication of Special Theory of Relativity
Re-examination of Energy Conservation Principle in Charged Capacitors and the Reported Anomalous Energy Devices
Estimating Physical Properties of Confirmed Exoplanets: I. Calculation of essential planetary properties-Possible M-R cataloging of exoplanets
The Wave Nature Phenomena and the Gravitational Field
Entropy Decrease in Isolated Systems: Theory, Fact and Tests
Tweets by @Fundamentaljour
Follow #Fundamental Journals
Prof. Maryam Mirzakhani
was an Iranian Mathematician & Stanford University Professor.
Fields Medal made by Stefan Zachow for the International Mathematical Union (IMU)
Maryam Mirzakhani was an Iranian Mathematician & Stanford University Professor. She was the first woman to win the Fields Medal-Known as the Nobel Prize of Mathematics in 2014 for "her outstanding contributions to the dynamics and geometry of Riemann surfaces and their moduli spaces".
Submit your Paper Online
ijfps@fundamentaljournals.org
fundamentaljournals@gmail.com
School of Engineering and the Built Environment
Birmingham City University, City Centre Campus
Millennium Point, Birmingham B4 7XG
All site content is licensed under Creative Commons Attribution 4.0 International License.
website designed Mr. Ali Balali
Copyright © 2022 Fundamental journals


text:
Oceans & Islands
Palila, Michael Walther, Oahu Nature Tours
Battling Mosquitoes
When it comes to saving Hawai'i's native birds, it takes a network of committed partners and innovative strategies. Both are key as we work to address the concern of mosquitoes to these endemic bird species.
'Apapane with mosquito on eye. Photo by Jack Jeffrey
Without bold and immediate action, up to 12 species of endemic Hawaiian honeycreepers will go extinct in the near future. The culprit will be deadly introduced diseases, such as avian malaria and pox. These pathogens are transmitted via nonnative mosquitoes, which, as the climate warms, are moving upslope into the birds' last forest strongholds. Just one bite from an infected mosquito is enough to kill the iconic 'I'iwi.
To combat this problem, ABC and partners are planning to use a naturally occurring bacteria as "birth-control" to reduce mosquito numbers in high-altitude forest bird habitat across the islands. The partnership is actively engaging community members to highlight the importance of this work for conserving Hawai'i's native birds. Engagement with stakeholders in Hawai'i is also ongoing to incorporate public feedback into the planning process.
As part of the multi-agency partnership, ABC is helping to coordinate the design and implementation of a strategy that will disrupt the mosquitoes' breeding cycle and cause their populations to crash. Under the plan, a secure lab would rear mosquitoes containing a strain of Wolbachia bacteria that makes them unable to successfully reproduce with wild females in Hawai'i. Only male mosquitoes, which don't bite birds or people, and therefore don't transmit the diseases, would be released. When wild female mosquitoes mate with the released males, they will lay eggs that don't hatch.
Scaling up this proven technique is a key component of ABC and its partners' strategy to save Hawai'i's forest birds from extinction. Done across a landscape scale, this method could dramatically reduce mosquito populations.
Wolbachia is found in over 60 percent of arthropod species, and poses no risk to humans. In fact, this safe, proven method is being used to stop the mosquito-borne transmission of human diseases such as dengue, Zika, chikungunya, and others.
Over the next three years, ABC and project partners will collect data on mosquito abundance and distribution to construct a successful implementation strategy, while also developing and testing the "birth-control" efficacy of the Wolbachia mosquitoes. These results will help inform the regulatory process, which includes securing required state and federal permits for the project.
Chris Farmer, ABC's Hawai'i Program Director, answers some questions about this project in the 2020 winter issue of Bird Conservation.
To learn more about this project visit the official project website hosted by Hawai'i Department of Land and Natural Resources: https://dlnr.hawaii.gov/mosquito/
To make a donation to support this effort, click here!
PROGRAM LEAD:
Chris Farmer
Hawai'i Program Director


On an average, one farm worker per week dies in the United States because of low-hanging power lines. The utility company who owns and operates the line is often negligent for failing to maintain the line at the required height. Even if the line has recently been worked on, the height of the line may still be lower than the required minimum. Trees are also an issue. If the utility company fails to trim or remove trees beneath the power line to insure sufficient clearance, injury, or even death, may occur.
If there is an injury or death due to contact with a power line, you should contact a skilled attorney to conduct an investigation to determine if negligence was a factor. In addition to utility company liability, an on-site supervisor hired as a contractor can also be held responsible for failing to secure safety at the site. Depending on the circumstances, various other entities or persons may be liable. We urge you to contact the Law Office of Laurie D. Mitchell if low-hanging power lines have caused injury or death of someone you know or love. Call 352-371-9828.


Each autumn we transit the astrological house of Scorpio, notorious for decadence, depression, decay, and death. Midway, we mark the annual festival of All Hallow's Eve, a grim celebration sounded with dark ambient descents, dense drones, and doleful emanations. On this Halloween transmission of HEARTS of SPACE, it's a journey to THE DARK SIDE.
Music is by RAISON D'ETRE, CIRCULAR, JOCELYN MONTGOMERY & DAVID LYNCH, TOR LUNDVALL, BETWEEN INTERVAL, ATTRITION, PAUL VNUK JR. & OOPHOI, ANDREW LILES, SKY BURIAL, NORTHERN VALENTINE, and PSICODREAMICS.
The first movement of BEETHOVEN's famous Piano Sonata No.14 in C Sharp Minor, better known as the "Moonlight Sonata." The nickname came from a German music critic in 1832 who impressionistically compared the effect to "moonlight shining on Lake Lucerne."
Beethoven intended it as a prelude, but in the score he instructed the performer to keep the sustain pedal down for the entire movement — a kind of special effect that mixed the music with natural harmonic reverberation from the piano. With its hypnotic triplets and ghostly melody, for Ambient music fans, it's one of the simplest, yet most memorable pieces ever written.
Beethoven may have inadvertently started a movement to redefine the piano as an instrument for contemplative, spatially expanded music, seeding the Impressionism of Debussy, the early ambient music of Satie, and laying the foundations of modern Minimalism.
On this transmission of Hearts of Space... a program of quiet night music for piano called NOCTURNES. Featured artists are MICHAEL DULIN, KEVIN KELLER, BRUCE LEVINGSTON, JENNY LIN, RALPH ZURMUHLE, LUDOVICO EINAUDI, and CHAD LAWSON.


Three decades in the water sports business has taught Hyperlite how to make an awesome wakeboard. The Hyperlite Wakeboards made their way onto the scene with the creation of the wakeboarding sport. When it comes to Hyperlite, you can expect high-quality boards with plenty of tech in them to give you everything you want from high arcing pops off the wake to grinding the rails in the cable park.
Hyperlite offers plenty of options for all kinds of riders. From the youngest to the most seasoned, if you ride a wakerboard, water ski or jet ski, you'll find the right fitting Hyperlite Life Vest for you.
Hyperlite has life vests are versatile so if you plan on having a bunch of people visit throughout the summer then you'll want life vests that accommodate all sizes. Even life vests for infants to juniors to teens are available. What's great about the Hyperlite toddler and infant life vests is that they tend to have a strap to go between their legs for added support and protection as well as grab handles to make it easy to pull them back into the boat if you need to.
The materials are high quality and will keep you afloat whether you're trying to slip your skis back on or waiting for the boat to circle around to pick you up after you flew off the towable tube. Most of the adult Hyperlite Life Vests feature a zipper with two buckles for maximum comfort and protection.
Hyperlite worked with the Hawaii and surf-inspired H.O. Sports to create compression-molded and neutral buoyancy wakeboards which are the standard in today's boards. It's through the collaboration that Hyperlite continues to bring competitive and high-performance products to the market. From wakeboards to wakesurfers and life vests to board bags, you'll find it all when you search Hyperlite.


salient issue they don ' t make prophesy on.
turned out to be wide of the mark .
winner of the election .
everything in existence in a foolish way .
name starts with letter ' S ' .
defeat in the presidential election .
grace to rule Nigeria again .
11, 262 , 978 .
election was entirely different from others .
would emerge winner of the election .
presidential election was concerned .
roundly defeated by Atiku .
next presidential election come 2019.
Atiku would trounce Buhari in the election .
Buhari sat majestically on it .
time God will look and changed His mind .
God changed his mind .
said . " After that utterance , the video ended.
prophecies don' t come to pass .
genuine men of God .
who do that are not genuine men of God .
stages of a prophetic word.
different from men ' s.
buttressing his point further .
them out to the public .
teach them how to administer it.


and Smooth Away Unwanted Cellulite.
*Some restrictions apply, ask for details. Offers expire August 31st, 2015. Limit one item per patient and offers may be pre-purchased for later use. Offers good while supplies last or schedule permits. Offers may not be combined with any other discounts, incentives or promotions. Patients must be candidates for service, procedure or product as determined by Dr. Parker and/or Medical Spa Professional.


As the awards season kicks off this year, we wanted to take a moment to thank The Webby Awards for naming our MSNBC.com app as an honoree for best news app on handheld devices. The official honoree distinction is awarded to the top 15% of all entries that exhibit remarkable achievement to the International Academy of Digital Arts and Sciences (IADAS). The judging panel, comprised of web industry experts, including media mogul Arianna Huffington, Skype CEO Tony Bates, and Instagram co-founder Kevin Systrom, selected our MSNBC.com app among the best from the nearly 10,000 entries this year. We're flattered to receive this recognition from the IADAS, and thank our partners at MSNBC.com for their commitment to and support for this app. Zumobi is pleased and humbled to be noticed among internet and media elites for its work and leadership within the mobile industry.
Want to check our award-winning app for yourself? Click here to download the app for your iPhone, iPad,, Android device or Kindle Fire.


text:
Emerging Technologies and Therapeutics
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)
Matthew C. Riddle1⇑,
Geremia B. Bolli2,
Monika Ziemen3,
Isabel Muehlen-Bartmer3,
Florence Bizet4 and
Philip D. Home5
on behalf of the EDITION 1 Study Investigators
1Oregon Health & Science University, Portland, OR
2Department of Medicine, Perugia University Medical School, Perugia, Italy
3Sanofi Deutschland GmbH, Frankfurt am Main, Germany
4Sanofi, Paris, France
5Newcastle University, Newcastle upon Tyne, U.K.
Corresponding author: Matthew C. Riddle, riddlem{at}ohsu.edu.
Diabetes Care 2014 Oct; 37(10): 2755-2762. https://doi.org/10.2337/dc14-0991
Suppl Material
OBJECTIVE To compare the efficacy and safety of new insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in people with type 2 diabetes on basal insulin (≥42 units/day) plus mealtime insulin.
RESEARCH DESIGN AND METHODS EDITION 1 (NCT01499082) was a 6-month, multinational, open-label, parallel-group study. Adults with glycated hemoglobin A1c (HbA1c) 7.0–10.0% (53–86 mmol/mol) were randomized to Gla-300 or Gla-100 once daily with dose titration seeking fasting plasma glucose 4.4–5.6 mmol/L. Primary end point was HbA1c change from baseline; main secondary end point was percentage of participants with one or more confirmed (≤3.9 mmol/L) or severe nocturnal hypoglycemia from week 9 to month 6.
RESULTS Participants (n = 807) had mean age 60 years, diabetes duration 16 years, BMI 36.6 kg/m2, and HbA1c 8.15% (65.6 mmol/mol). HbA1c reduction was equivalent between regimens; least squares mean difference –0.00% (95% CI –0.11 to 0.11) (–0.00 mmol/mol [–1.2 to 1.2]). Fewer participants reported one or more confirmed (≤3.9 mmol/L) or severe nocturnal hypoglycemic events between week 9 and month 6 with Gla-300 (36 vs. 46% with Gla-100; relative risk 0.79 [95% CI 0.67–0.93]; P < 0.005); nocturnal hypoglycemia incidence and event rates were also lower with Gla-300 in the first 8 weeks of treatment. No between-treatment differences in tolerability or safety were identified.
CONCLUSIONS Gla-300 controls HbA1c as well as Gla-100 for people with type 2 diabetes treated with basal and mealtime insulin but with consistently less risk of nocturnal hypoglycemia.
Long-acting (basal) insulin analogs have contributed significantly to the management of diabetes over the last decade. The first and most commonly used analog is insulin glargine 100 units/mL (Gla-100) (1,2), which has a well-established mode of action and profile of efficacy and safety (3–6). It has advantages compared with human NPH insulin, notably reduction of nocturnal and overall hypoglycemia (2,7,8). This benefit is clinically relevant because, in addition to concern about medical risks associated with hypoglycemia, fear of hypoglycemia is a leading barrier to starting insulin therapy (9–11). However, hypoglycemia continues to be observed during Gla-100 treatment, suggesting that a basal insulin with an even flatter and longer profile of action might further improve safety and tolerability.
The new insulin glargine 300 units/mL (Gla-300) has a reduced redissolution rate following subcutaneous injection as compared with Gla-100 and thereby the potential for meeting this need (12,13). Glucose clamp studies confirm that Gla-300 provides flatter and more prolonged pharmacokinetic and pharmacodynamic profiles than Gla-100 (12,13). To determine whether these properties will translate to clinical benefits, the phase 3a EDITION program is assessing the efficacy and safety of Gla-300 compared with Gla-100 in different patient populations. EDITION 1, the first of these studies to be completed, enrolled people with type 2 diabetes not adequately controlled despite previously using ≥42 units/day of basal insulin together with mealtime insulin. This represents a potentially challenging and growing population of people with long-duration type 2 diabetes, who require high-dose basal insulin and mealtime insulin therapy.
Study Design and Participants
EDITION 1 was a multicenter, open-label, parallel-group study conducted in 13 countries (three in North America, nine in Europe, and in South Africa) between 15 December 2011 and 30 January 2013. Appropriate ethics committees approved the protocol, which was conducted according to Good Clinical Practice and the Declaration of Helsinki. All participants provided written, informed consent. Entry criteria included age ≥18 years with type 2 diabetes (World Health Organization definition) (14); use of basal and mealtime insulin therapy, including current basal therapy with ≥42 units/day of either Gla-100 or NPH, together with mealtime therapy with insulin lispro, aspart, or glulisine with or without metformin for at least 1 year; and glycated hemoglobin A1c (HbA1c) 7.0–10.0% (≥53 to ≤86 mmol/mol). Exclusion criteria included use of human mealtime insulin or any premixed or basal insulin other than insulin glargine or NPH; oral glucose-lowering drugs other than metformin in the last 3 months or injected glucose-lowering agents other than insulin; and any history of proliferative diabetic or other unstable retinopathy or clinically important cardiac, renal, hepatic, or other systemic disease.
Randomization and Masking
Participants were randomized (1:1) to receive once-daily injections of either Gla-300 (Sanofi, using a modified SoloSTAR pen injector) or Gla-100 (Lantus [Sanofi], using a SoloSTAR pen). The SoloSTAR pen injectors both delivered the same volume (0.01 mL) per "click." The precision of the modified version of the SoloSTAR device was adequate for use with Gla-300 at starting doses at or above 39 units, so that a single downward titration of 3 units from 42 to 39 units daily could be done with acceptable accuracy. Randomization used a centralized interactive voice or internet response system (block size 4) and was stratified by HbA1c <8.0 and ≥8.0% (<64 and ≥64 mmol/mol) at screening. Due to differences in the injection devices, this was an open-label study. A 6-month open-label extension followed the main treatment period; here we report only the main treatment period.
Participants were given a glucose meter and test strips and educated in their use, including recording self-measured plasma glucose (SMPG) results in a diary. For participants previously using Gla-100 or once-daily NPH, the starting dose of Gla-300 or Gla-100 was the basal insulin dose used the 3 days prior to randomization; for those previously taking NPH more than once daily, the new daily basal dose was reduced by ∼20%. Injections were to be given in the evening from before dinner to bedtime but at the same time for each individual during 6 months of randomized treatment. Starting basal doses at randomization were divisible by 3, rounding down if necessary. When more than one basal insulin injection was needed to deliver the required dosage (>80 units with Gla-100; >180 units with Gla-300), split injections were given at the same time. Basal insulin dosage was generally adjusted weekly, and no more often than every 3 days, aiming for a prebreakfast SMPG of 4.4–5.6 mmol/L based on the median of the previous 3 days. Adjustments were restricted by protocol in both groups to changes divisible by 3 units, the smallest adjustment possible for Gla-300 because of the characteristics of the pen injector. Dosage was to increase by 3 units for >5.6 and <7.8 mmol/L and by 6 units if ≥7.8 mmol/L, and it was to decrease by 3 units if SMPG readings were <4.4 mmol/L or at the discretion of the investigator. Mealtime insulin doses were adjusted at the discretion of the investigator after basal insulin had been optimized but could be reduced earlier if needed when basal dosage was increased. Mealtime dose titration could be based on either postmeal SMPG (target range 6.7–8.9 mmol/L) or on values before the following meal or at bedtime (5.0–7.2 mmol/L). Metformin was to continue at prior dosage throughout the study. Beyond this guidance, investigators and participants were expected to use individual judgment in cessation of titration or other adjustments for reasons of safety.
Assessment visits occurred at screening (week –2); baseline; weeks 2, 4, 8, and 12; and months 4 and 6. Interim telephone contacts were scheduled at weeks –1, 1, 3, 5–7, and 9–11. Samples for central measurement of HbA1c and fasting plasma glucose (FPG) concentration were collected at baseline, week 12, and month 6. Eight-point SMPG profiles (before and 2 h after breakfast, lunch, and dinner and at bedtime and 0300 h) were performed before baseline and at all later study visits.
The primary end point was HbA1c change from baseline to month 6 or the last visit on treatment. The main secondary efficacy end point was the percentage of participants with one or more confirmed (≤3.9 mmol/L) or severe nocturnal (0000–0559 h) hypoglycemic events, reported between the start of week 9 and month 6. Other secondary end points included change from baseline in FPG; percentage of participants attaining HbA1c <7.0% (53 mmol/mol) and ≤6.5% (48 mmol/mol) or FPG ≤6.7 and <5.6 mmol/L; changes of mean and variability of 24-h plasma glucose based on 8-point SMPG profiles; change in preinjection SMPG and change in variability of preinjection SMPG; and changes of basal and total daily insulin doses and of body weight. Percentages of participants with hypoglycemic events and annualized event rates were calculated as categorized by the American Diabetes Association and were analyzed during the day (daytime; 0600–2359 h), during the night (nocturnal; 0000–0559 h), and any time of day or night (24 h) (15). Specifically, hypoglycemic categories included the following: 1) any hypoglycemia (events whether confirmed by SMPG or not and whether symptomatic or asymptomatic); 2) documented symptomatic hypoglycemia (symptomatic events with SMPG ≤3.9 mmol/L); 3) asymptomatic hypoglycemia (events confirmed by SMPG ≤3.9 mmol/L but without symptoms); and 4) severe hypoglycemia (events requiring assistance by another person to administer carbohydrate, glucagon, or other therapy). In addition to the threshold of ≤3.9 mmol/L, hypoglycemic events with a plasma glucose of <3.0 mmol/L were analyzed separately. Confirmed or severe hypoglycemia included documented symptomatic or asymptomatic events together with severe events.
Other adverse events (AEs), including injection-site reactions, were systematically recorded at each contact with investigators. Treatment satisfaction was assessed using the validated Diabetes Treatment Satisfaction Questionnaire (DTSQ), completed at baseline, week 12, and month 6 (16,17).
Data Analysis and Statistics
Analyses were performed using SAS version 9.2 (Cary, NC). A sample size of 800 evaluable participants was estimated to give 99% power for the upper confidence limit of the mean difference in change of HbA1c between insulin formulations not to exceed 0.4% (4.4 mmol/mol), assuming that the SD of change is 1.3% (14.2 mmol/mol), for a true difference of 0.0%. Primary efficacy and secondary end points used the modified intent to treat (mITT) population, defined as all randomized participants who received at least one dose of study insulin and had both a baseline and one or more postbaseline assessment. If a participant discontinued treatment prematurely or did not have an efficacy measurement at month 6, the last postbaseline efficacy measurement was used (last observation carried forward procedure). Safety analyses included all participants randomized and exposed to one or more doses of study insulin.
To assess noninferiority for the primary end point, the upper bound of the two-sided 95% CI, estimated by a covariance (ANCOVA) model, was compared with the predefined noninferiority margin (HbA1c <0.4%; <4.4 mmol/mol). If noninferiority was demonstrated for HbA1c, superiority was to be tested for HbA1c (one-sided α = 0.025) and the main secondary efficacy end points according to a hierarchical testing procedure. All continuous secondary efficacy variables were analyzed using either ANCOVA (all except for change in variability of plasma glucose) or ANOVA (change in variability) models. Categorical secondary efficacy variables (responder rates) were analyzed using a Cochran-Mantel-Haenszel method stratified according to screening HbA1c (<8.0 and ≥8.0% [<64 and ≥64 mmol/mol]). AEs were coded using the MedDRA system.
Role of Funding Source
Sanofi was the sponsor and designed and coordinated the study, monitored clinical sites, collected and managed the data, and performed statistical analyses. M.C.R., G.B.B., and P.D.H. took part in protocol design, data interpretation, and manuscript writing. All authors had full access to the study data and had final responsibility to submit the article for publication.
Of 807 participants randomized to Gla-300 (n = 404) or Gla-100 (n = 403), 404 and 402, respectively, received study insulin (safety population), and 404 and 400 formed the mITT population (Supplementary Fig. 1). Treatment was discontinued before 6 months by 30 (7.4%) of 404 participants on Gla-300 and 31 (7.7%) of 403 on Gla-100. The two groups had similar characteristics at baseline (Table 1). Participants had a mean age of 60 years, duration of diabetes of 16 years, BMI of 36.6 kg/m2, HbA1c of 8.15% (65.6 mmol/mol), FPG of 8.9 mmol/L (160 mg/dL), and basal and total insulin doses of 0.67 and 1.20 units/kg/day.
Baseline characteristics of all randomized participants
Glycemic Responses and Insulin Dosage
Mean HbA1c decreased similarly in the two treatment groups (Fig. 1A). At the end of treatment, HbA1c was 7.25% (SD 0.85) (55.7 mmol/mol [9.3]) with Gla-300 and 7.28% (0.92) (56.1 mmol/mol [10.1]) with Gla-100. The least squares (LS) mean change was –0.83% (SE 0.06) (–9.1 mmol/mol [0.7]) for both groups; difference –0.00% (95% CI –0.11 to 0.11) (–0.00 mmol/mol [–1.2 to 1.2]), thus meeting the noninferiority criterion. Similar reductions in laboratory-measured FPG from baseline were observed in both treatment groups (from 8.72 mmol/L [SD 2.83] to 7.24 mmol/L [2.57] with Gla-300 and 8.90 mmol/L [2.94] to 7.21 mmol/L [2.40] with Gla-100) (Fig. 1B). The percentages of participants attaining target HbA1c levels were similar with Gla-300 and Gla-100 (39.6 and 40.9% for HbA1c <7.0% [53 mmol/mol] and 26.5 and 23.2% for FPG <5.6 mmol/L, respectively) (Supplementary Table 1).
Clinical measures during treatment in the mITT population by visit and with last observation carried forward (LOCF). A: HbA1c. B: FPG. C: Daily basal insulin and mealtime insulin dosage.
Daily basal insulin dosage increased from 0.67 units/kg/day (SD 0.29) to 0.97 units/kg/day (0.37) (70 units/day [32] to 103 units/day [42]) at the end of the 6-month treatment period with Gla-300 and from 0.67 units/kg/day (0.28) to 0.88 units/kg/day (0.32) (71 units/day [33] to 94 units/day [38]) with Gla-100; LS mean difference 0.09 units/kg/day (SE 0.02) (95% CI 0.062–0.124) (Fig. 1C). Mealtime insulin doses increased slightly in the first 2 weeks but were unchanged from baseline and alike in the two groups thereafter (final 0.55 units/kg/day [SD 0.35]). Final total daily dosage was 1.53 units/kg/day (0.61) with Gla-300 and 1.43 units/kg/day (0.60) with Gla-100. Body weight increased by 0.9 kg in both treatment groups.
The SMPG profiles declined in both treatment groups (Supplementary Fig. 2 and Supplementary Table 1). The mean of all daily measurements declined to the same degree with each treatment, and no significant differences between changes in means at individual time points were demonstrated, including comparisons of fasting, 0300 h, and preinjection measurements. The reduction of preinjection SMPG (combination of pre- and postdinner measurements) from baseline to month 6 was similar between treatments (LS mean change –0.90 mmol/L [SE 0.18] and –0.84 mmol/L [0.18]). There was also no between-treatment difference in the change of day-to-day variability of preinjection SMPG during treatment.
Curves displaying the cumulative mean number of nocturnal (Fig. 2A) and any time (Fig. 2B) confirmed or severe hypoglycemic events during the course of treatment are shown in Fig. 2.
Cumulative mean numbers of confirmed (plasma glucose ≤3.9 mmol/L [70 mg/dL]) or severe hypoglycemic events per participant during the main 6-month treatment period in the safety population. A: Nocturnal events. B: Events at any time of day or night (24 h).
The proportion of participants with one or more confirmed (≤3.9 mmol/L) or severe nocturnal hypoglycemic events between the start of week 9 and month 6 was 36% (146 of 404) on Gla-300, compared with 46% (184 of 400) on Gla-100. Analysis of this prespecified main measure of hypoglycemia demonstrated superiority of Gla-300 over Gla-100 with a significantly lower relative risk (RR 0.79 [95% CI 0.67–0.93], P = 0.0045). The percentages of participants affected and rates of events per participant-year of exposure for other intervals of time and categories of hypoglycemia are shown in Supplementary Tables 2 and 3; RRs are shown in Fig. 3. With the exception of severe nocturnal hypoglycemic events, which were too few for meaningful analysis, the percentage of participants within each category of nocturnal events (any hypoglycemia; documented [≤3.9 and <3.0 mmol/L] symptomatic hypoglycemia; and confirmed [≤3.9 and <3.0 mmol/L] or severe hypoglycemia) was lower with Gla-300 than with Gla-100 (RR 0.72–0.78) throughout the course of treatment. Likewise, annualized rates for nocturnal events were lower with Gla-300 (RR 0.60–0.78) across all categories of hypoglycemia other than severe events.
RRs of hypoglycemic events at any time of day or night (24 h) or during the night alone (nocturnal) with Gla-300 vs. Gla-100 during 6 months of treatment in the safety population. A: Risk of at least one hypoglycemic event per participant. B: Risk of events per participant-year of exposure. Total participant-year: baseline to month 6: Gla-300, 195 and Gla-100, 193; baseline to week 8: Gla-300, 63 and Gla-100, 62; week 9 to month 6: Gla-300, 132 and Gla-100, 131. 95% CIs are shown.
No significant increase in either the numbers of participants affected or annualized rates for daytime hypoglycemia was apparent in any category. Risks of any time events, nocturnal and daytime together, were equivalent or lower with Gla-300. The percentage of participants reporting severe hypoglycemia at any time of day or night (24 h) was similar for the two groups: 5.0% for Gla-300 vs. 5.7% for Gla-100 (RR 0.87 [95% CI 0.48–1.55]).
Treatment Satisfaction
Treatment satisfaction scores, as measured by the DTSQ, were similar between treatment groups and generally increased from baseline to month 6, with a small between-treatment difference in favor of Gla-300 versus Gla-100 (treatment satisfaction scores increased in 63 and 58% of participants, respectively) (Supplementary Table 4). The perceived frequency of hypoglycemia, as captured by Item 3 of the DTSQ, was similar between groups. The cumulative distribution functions of Item 3 show that at month 6, more than half of the participants experienced a decrease from baseline in the perception of hypoglycemia, with a small between-treatment difference in favor of Gla-300 (change from baseline to month 6: ≤0 in 59 and 54% of participants in the Gla-300 and Gla-100 groups, respectively).
The most common AEs were infections, gastrointestinal events, or musculoskeletal complaints; these were equally distributed between the groups. Injection-site reactions were reported by nine (2.2%) and six (1.5%) people treated with Gla-300 and Gla-100, respectively. Serious treatment-emergent AEs (Supplementary Table 5) were reported by 26 people (6.4%) on Gla-300 and 21 (5.2%) on Gla-100, with a maximum of two events of any one type of event for both insulins, including two of hypoglycemic coma on Gla-300. Treatment-emergent AEs led to withdrawal from the study in six (1.5%) people in the Gla-300 group and seven (1.7%) in the Gla-100 group. Three participants experienced a serious treatment-emergent AE with fatal outcome during the study, one in the Gla-300 group (bronchogenic carcinoma) and two in the Gla-100 group (one with multidrug intoxication associated with recurrent depression and one with chronic heart and kidney failure). Two additional participants in the Gla-300 group had an AE with fatal outcome 4 and 12 days after treatment discontinuation (due to pulmonary embolism and infected thrombosis and heart embolism, respectively). No deaths were considered related to study medication.
This large, randomized, 6-month efficacy and safety study of Gla-300 enrolled a population of people with type 2 diabetes using mealtime insulin with basal insulin at a dosage of at least 42 units/day. This dosage requirement was selected to ensure adequate dose precision with the pen injector used for Gla-300. Improvements of HbA1c, FPG, and profiles of SMPG were essentially the same with Gla-300 as with Gla-100. Attainment of mean HbA1c 7.3% (56 mmol/mol) by each group suggests good adherence to basal insulin titration by the site investigators and study participants. Similar levels of glycemic control have been reported in other studies of type 2 diabetes requiring regimens including both basal and mealtime insulin (18–20). Despite equivalent efficacy in terms of glycemic control, use of Gla-300 resulted in a 10% absolute and 21% relative decrease in risk of experiencing at least one confirmed or severe nocturnal hypoglycemic event from week 9 to month 6. This time period was chosen to avoid any possibility of temporary alteration of the risk of hypoglycemia following a switch from a known therapy (in most cases Gla-100) to an unfamiliar new insulin. However, the between-treatment differences observed in both incidence and event rate of nocturnal hypoglycemia, favoring Gla-300, were apparent both in the first 8 weeks and later in the course of treatment, as is visually evident in Fig. 2. This appears different from the experience with insulin degludec, another new long-acting analog, where differences in nocturnal hypoglycemia seem to emerge later, for reasons that are unclear (21). Insulin glargine (Gla-100) is already known to give lower rates of nocturnal hypoglycemia than NPH insulin (2,7,8), so the current results are doubly encouraging.
This observation was further supported by the consistency of patterns of events regardless of the category of hypoglycemia, which were all equivalent between the two insulins or favored Gla-300. Notably, the RR of confirmed (≤3.9 mmol/L) or severe nocturnal hypoglycemia was 21% lower with Gla-300 during the first 8 weeks of the study, 21% lower from week 9 to the end of treatment, and 22% lower for the whole treatment period. Similarly, the rate of nocturnal confirmed or severe events (including multiple events for an individual over the course of the study) was 25% lower with Gla-300. None of the categories of hypoglycemia showed an increase of events with Gla-300 during the daytime (0600–2359 h), and severe hypoglycemia was uncommon with both treatments.
Differences of study design and populations limit comparison of the present findings with other studies of longer-acting insulin using treat-to-target protocols, but the published experience nevertheless is of interest. In the original Treat-to-Target study, which enrolled insulin-naive participants, initiation and titration of Gla-100 resulted in an annualized rate of confirmed hypoglycemic events (≤4.0 mmol/L) that was 29% lower than observed with NPH insulin, and the rate of confirmed nocturnal events was 44% lower (2). Subsequent studies in previously insulin-naive people have shown reductions in hypoglycemia with Gla-100 or insulin detemir relative to NPH insulin that are of about the same magnitude (22). Two similarly designed studies have evaluated beginning treatment with insulin degludec compared with Gla-100 (21,23). These are of interest because degludec, like Gla-300, is reported to have an action profile extending beyond 24 h. In one of these studies, the annualized rate of nocturnal hypoglycemia confirmed <3.1 mmol/L was 36% lower (P = 0.038) with insulin degludec U100 versus Gla-100 (21). In the other, a U200 formulation of insulin degludec was associated with a nominally but nonsignificantly lower rate of confirmed (<3.1 mmol/L) nocturnal hypoglycemia compared with Gla-100 (RR 0.86, P = 0.46) (23). Collectively, these studies of insulin-naive populations suggest that Gla-100 and insulin detemir confer lower risks of hypoglycemia than NPH insulin, whereas the longer-acting insulin degludec may have even less tendency to cause nocturnal hypoglycemia than Gla-100.
A recent comparison of insulin degludec U100 with Gla-100 in a population with type 2 diabetes that included people who were previously treated with basal and mealtime insulin more closely resembles the current study (24). Equivalent glycemic control was attained with degludec and Gla-100. The annualized rate of confirmed nocturnal hypoglycemic events was 25% (P = 0.040) lower with insulin degludec than with Gla-100. These findings are similar to those of the current study, but again the comparison is limited by differences in the populations examined. The current study has a different definition of confirmed hypoglycemia (≤3.9 vs. <3.1 mmol/L) and enrolled participants with higher BMI (36.6 vs. ∼32 kg/m2), longer duration of diabetes (∼16 vs. ∼13.5 year), more frequent prior use of mealtime as well as basal insulin therapy (100 vs. ∼50%), and higher basal insulin doses (0.7 vs. ∼0.4 units/kg).
Some additional questions remain. The 10% higher dosage of Gla-300 at the end of treatment might be due to a slight decrease in bioavailability related to a longer subcutaneous residence time with exposure to tissue peptidases. The glargine molecule is unchanged in Gla-300, therefore new safety concerns appear unlikely; the main circulating molecule is 21A-Gly-human insulin (metabolite M1) after injection with each formulation (25). No evidence of increased injection-site problems or other AEs appeared in this study, but more participant-years of observation will be needed to confirm long-term safety. Finally, it remains to be shown whether other populations of people with diabetes will experience similar, or perhaps greater, reductions in risk of hypoglycemia with Gla-300. Strengths of this study include enrollment of a relatively large number of people representing a growing population with long-duration type 2 diabetes requiring high-dose basal insulin and mealtime insulin therapy; a closely supervised titration scheme to optimize basal insulin delivery leading to good and equivalent glycemic control in each treatment group; and the consistency of the findings with different categories of hypoglycemia and different intervals of time in the study. Limitations include the unavoidable open-label nature of the protocol, relatively short duration of study, and limited titration of mealtime insulin doses. Although the obesity and high insulin requirement of the EDITION 1 population are now common in type 2 diabetes, the results of this study cannot be generalized to the whole population of people with insulin-requiring diabetes, which includes many taking <42 units of basal insulin daily. Completion of later EDITION studies will address the last concern. Further details regarding the rationale for use of Gla-300 in both EDITION 1 and the rest of the EDITION studies are available in a video presentation (Video 1, available at http://bcove.me/psne9yp6).
In conclusion, EDITION 1 showed the new insulin Gla-300, administered for 6 months, improved glycemic control for obese people with long-duration type 2 diabetes as well as Gla-100 but with less nocturnal hypoglycemia and no increase of daytime hypoglycemia. No between-treatment differences in the safety profile were identified. Gla-300 is being further investigated in studies of other populations in the EDITION program.
Acknowledgments. The authors thank the study participants, trial staff, and investigators for their participation. Principal investigators at the clinical sites are listed in the Supplementary Data. Editorial assistance was funded by Sanofi and provided by Sarah Hines of Fishawack Communications (Abingdon, United Kingdom).
Duality of Interest. This study was funded by Sanofi. Sanofi was the sponsor of the study and was responsible for the design and coordination of the trial. Sanofi monitored the clinical sites, collected and managed the data, and performed all statistical analyses.
M.C.R. received research grant support from Amylin, Eli Lilly and Company, and Sanofi and honoraria for consulting and/or speaking from Amylin, Bristol-Myers Squibb-AstraZeneca Alliance, Elcelyx, Eli Lilly and Company, Hoffmann-La Roche, Sanofi, and Valeritas. These dualities of interest have been reviewed and managed by Oregon Health & Science University. G.B.B. received honoraria for advising and lecturing from Sanofi, Eli Lily and Company, and Novartis. M.Z., I.M.-B., and F.B. are employees of Sanofi. P.D.H. received funding for self or affiliated institutions from Bristol-Myers Squibb-AstraZeneca Alliance, Eli Lilly and Company, GlaxoSmithKline, Janssen/J&J, Merck, Novo Nordisk, Roche Diagnostics, Roche Pharma, Sanofi, SkyePharma, and Takeda. No other potential conflicts of interest relevant to this article were reported.
Author Contributions. M.C.R., G.B.B., and P.D.H. participated in the design of the study program and the study protocol and in writing, reviewing, and editing the manuscript. M.Z., I.M.-B., and F.B. reviewed and edited the manuscript. M.C.R. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Clinical trial reg. no. NCT01499082, clinicaltrials.gov.
This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc14-0991/-/DC1.
A slide set summarizing this article is available online.
This article contains video online at http://dx.doi.org/10.2337/dc14-0991.
Received April 18, 2014.
Accepted June 12, 2014.
© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
Owens DR
. Insulin preparations with prolonged effect. Diabetes Technol Ther 2011;13(Suppl. 1):S5–S14pmid:21668337
Riddle MC,
Rosenstock J,
Gerich J,
Insulin Glargine 4002 Study Investigators
. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080–3086pmid:14578243
Bolli GB,
Andreoli AM,
Lucidi P
. Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era. Diabetes Technol Ther 2011;13(Suppl. 1):S43–S52pmid:21668336
ORIGIN Trial Investigators
. Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial. Diabetes Care 2013;36:2915–2922pmid:23656980
Gerstein HC,
Bosch J,
Dagenais GR,
. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319–328pmid:22686416
Inzucchi SE,
Bergenstal RM,
Buse JB,
American Diabetes Association (ADA),
European Association for the Study of Diabetes (EASD)
. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379pmid:22517736
Janka HU,
Plewe G,
Kliebe-Frisch C,
Schweitzer MA,
Yki-Järvinen H
. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254–259pmid:15677775
Yale JF,
Harris SB,
Issa M,
Stewart JA,
Dempsey E
. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006;23:736–742pmid:16842477
Davies M
. The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes Relat Metab Disord 2004;28(Suppl. 2):S14–S22pmid:15306833
Cryer PE
. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002;45:937–948pmid:12136392
Korytkowski M
. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26(Suppl. 3):S18–S24pmid:12174319
Tillner J, Bergmann K, Teichert L, et al. Euglycemic clamp profile of new insulin glargine U300 formulation in patients with type 1 diabetes (T1DM) is different from glargine U100 (Abstract). Diabetes 2013;62:A920-P
Dahmen R,
Bergmann K,
Lehman A,
. New insulin glargine U300 formulation evens and prolongs steady state PK and PD profiles during euglycemic clamp in patients with type 1 diabetes (T1DM) (Abstract). Diabetes 2013;62:A113
World Health Organization. Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Organization, 1999. Available from http://whqlibdoc.who.int/hq/1999/who_ncd_ncs_99.2.pdf. Accessed 6 November 2013
American Diabetes Association Workgroup on Hypoglycemia
. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005;28:1245–1249pmid:15855602
Bradley C,
Lewis KS
. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabet Med 1990;7:445–451pmid:2142043
Lewis KS,
Knight G,
Boulton AJ,
Ward JD
. A measure of treatment satisfaction designed specifically for people with insulin-dependent diabetes. Diabet Med 1988;5:235–242pmid:2967144
Fritsche A,
Larbig M,
Owens D,
Häring HU,
GINGER study group
. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab 2010;12:115–123pmid:20092584
Meneghini L,
Mersebach H,
Kumar S,
Svendsen AL,
Hermansen K
. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. Endocr Pract 2011;17:727–736pmid:21550957
Vlajnic A,
. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes Metab 2014;16:396–402 pmid:24118931
Zinman B,
Philis-Tsimikas A,
Cariou B,
NN1250-3579 (BEGIN Once Long) Trial Investigators
. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012;35:2464–2471pmid:23043166
Hermansen K,
Davies M,
Derezinski T,
Martinez Ravn G,
Clauson P,
Home P
. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269–1274pmid:16732007
Gough SC,
Bhargava A,
Jain R,
Rasmussen S,
Bergenstal RM
. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care 2013;36:2536–2542pmid:23715753
Garber AJ,
King AB,
Del Prato S,
NN1250-3582 (BEGIN BB T2D) Trial Investigators
. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1498–1507pmid:22521072
Steinstraesser A,
Schmidt R,
Becker RH
. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab. 26 February 2014 [Epub ahead of print]pmid:24571126
October 2014, 37(10)
Masthead (PDF)
Thank you for your interest in spreading the word about Diabetes Care.
You are going to email the following New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)
Message Subject (Your Name) has forwarded a page to you from Diabetes Care
Message Body (Your Name) thought you would like to see this page from the Diabetes Care web site.
Matthew C. Riddle, Geremia B. Bolli, Monika Ziemen, Isabel Muehlen-Bartmer, Florence Bizet, Philip D. Home
Diabetes Care Oct 2014, 37 (10) 2755-2762; DOI: 10.2337/dc14-0991
Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial
Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System
Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study
Show more Emerging Technologies and Therapeutics


Paul opens his letter to Timothy, a young new preacher of the gospel, with encouragement. He points out that he was a horrible, rotten sinner, yet was shown much mercy and grace by God because he had done everything out of ignorance and unbelief.
The majority of the people in the world do not have the proper perspective on who they are or what they are really like. They do not see a need to be saved because they do not believe in sin. Not believing in God will cause a reason to not believe in sin. So people see themselves as a good person or just like everyone else.
There are believers in the church who tend to have the same view of themselves. This can be seen in believers who grew up in the church. They do believe in God and believe in sin, but never really saw themselves as a bad sinner.
Very few people will consider themselves as a blasphemer, persecutor and a violent person. Yet, every believer was these very things at one point in their life. They claimed that they could do anything and did not need God, even talking against God, being a blasphemer. They talked against believers, being a persecutor. And did things selfishly against others, being violent.
Yet, they were shown mercy by God, because most of what they had been doing was done in ignorance or unbelief. God knows that humans act the way they do because they don't really know the truth–Jesus and God's word. Jesus accepts and forgives everyone who comes to Him in belief.
As a believer you were once all of these things. Without Jesus you would still be in that position and be that type of person. Yet, Jesus has shown you His great mercy and forgiven you.
Since you have been forgiven, turn away from that type of living. Also realize that the rest of the world still needs to learn this truth. Be ready to show mercy on others, just as Jesus has shown you mercy.
Having the right perspective on who you were and who you are now, helps you know other people correctly. You were changed and saved, they can also be changed and saved.
I pray today that God will reveal to you who you were; that you will know the mercy God has given you; that you will be a changed person in Jesus; that you will show God's mercy to others; and that God will help you turn from all sin.


Make photography even more fun, easier and more complete with the right camera accessories. Aside from an extensive selection of second-hand cameras, we also offer many second-hand accessories. If you don't need your accessory to be shiny and new, having the option of a second-hand product is ideal. You can find them here.
When you buy second-hand items from us, you can rest assured that you're buying a properly functioning product. After we receive the second-hand products, they are thoroughly checked by professionals. If you don't need to have the latest of the latest, second-hand products are a perfect buy. They are less expensive and for the same budget, you can shop in a 'higher' price range.
We thoroughly inspect all newly arrived second-hand products. That is why we offer a 1-year warranty on second-hand equipment. We will take care of any issues arising the first year. During the warranty period, we will arrange everything necessary to inspect, repair and return your product to you.
We offer a wide selection of other second-hand products in our webshop. Aside from offering you the best second-hand products for the best prices, we also aim to offer excellent service. You can contact our customer service for any questions you might have.


My day, hell my week has not gone exactly gone like I expected it to. I have not gotten to run like I want to, I skipped yesterday for my reasons then last night I was up sick all night long. It must have been something I ate because once I felt better instantly. I just was up way after midnight so I opted out of the run/walk this morning. I was kinda bummed about missing two days, if I had known I would have been sick I would have just gone on Monday and gotten the miles that I could.
I did get in a couple of workouts today. I swam with my swimming friend today, she is back to school so we are back to swimming. And she did very good today! Then to my amazement, I was called before I left work and invited to run with my NoBo group so I ended up getting to run after all. Yeah! I have discovered that I run much better in the afternoon than I do in the morning.
Tomorrow I have to teach the toning class again so I will miss some of my run but after reading an article in Runners World I have a special program for us tomorrow....hills! One of my running buddies is out because of an injury and the other one agreed to do it with me so hahaha I am running hills tomorrow. It makes me laugh because I do everything in my power to avoid hill and tomorrow that is all I am going to do. I need to get stronger.
I have also gotten on a new kick here lately. I have been Juicing (not steroids) but fruits and veggies. I dont like to eat many veggies so I thought this might be a way to get them in without actually having to eat them. So far it taste really gross but I am trying all kinds of new foods. I am that crazy person in the grocery that walks through the produce department and buys one of everything. Basically everything taste like celery so far. I am still trying out new combinations and even trying some solo, like kale, blah yuck!
If I find any that are exceptionally delicious I will let you know.
Ok, I must get into bed now cause I am going to run in the morning, no matter what....I need some miles this week and my new running shoes are feeling neglected.
By the way: This post has been typed up for a while now but my stupid internet keeps going in and out so I cant spell check or post it. Come on!
My week has not gone as planned either with my workouts and running so I'm right there with you. Glad you are feeling better!
Hello, I Should Be In BED!!!!
Being a Blogger is Sooooo HARD!!!!!
Look Who Came to Breakfast!
When the Results Don't Match the Effort!


The tenant improvement project for DGS included 2,500 sf of office space in this DC government building. Offices, conference rooms, and support spaces are enlivened by artwork from various city programs supporting community arts. The reception area was designed with a welcoming reception desk integrated with colorful accent walls. Materials + finishes were chosen for their sustainable properties.
The basement facilities were renovated with durable, high quality materials to provide ADA accessibility. A bright color scheme of blue and yellow was developed to offer lightness. Custom millwork ties together the sink counter, lockers, and bench.